Search

Your search keyword '"Parekh, Falgunee"' showing total 24 results
Start Over Author "Parekh, Falgunee"
24 results on '"Parekh, Falgunee"'

8. Building Scientific Capability and Reducing Biological Threats: The Effect of Three Cooperative Bio-Research Programs in Kazakhstan

Author

Yeh, Kenneth B., primary, Tabynov, Kairat, additional, Parekh, Falgunee K., additional, Maltseva, Elina, additional, Skiba, Yuriy, additional, Shapiyeva, Zhanna, additional, Sansyzbai, Ablay, additional, Frey, Stefan, additional, Essbauer, Sandra, additional, Hewson, Roger, additional, Richards, Allen L., additional, and Hay, John, additional

Published
2021
Full Text
View/download PDF

10. Significance of High-Containment Biological Laboratories Performing Work During the COVID-19 Pandemic: Biosafety Level-3 and -4 Labs

Author

Yeh, Kenneth B., primary, Tabynov, Kairat, additional, Parekh, Falgunee K., additional, Mombo, Illich, additional, Parker, Kyle, additional, Tabynov, Kaissar, additional, Bradrick, Shelton S., additional, Tseng, Ashley S., additional, Yang, Ji-Rong, additional, Gardiner, Lolly, additional, Olinger, Gene, additional, and Setser, Bradly, additional

Published
2021
Full Text
View/download PDF

13. Malaria

Author

Richie, Thomas L., primary and Parekh, Falgunee K., additional

Published
2009
Full Text
View/download PDF

15. Project IDentif.AI: Harnessing Artificial Intelligence to Rapidly Optimize Combination Therapy Development for Infectious Disease Intervention

Author

Abdulla, Aynur, primary, Wang, Boqian, additional, Qian, Feng, additional, Kee, Theodore, additional, Blasiak, Agata, additional, Ong, Yoong Hun, additional, Hooi, Lissa, additional, Parekh, Falgunee, additional, Soriano, Rafael, additional, Olinger, Gene G., additional, Keppo, Jussi, additional, Hardesty, Chris L., additional, Chow, Edward K., additional, Ho, Dean, additional, and Ding, Xianting, additional

Published
2020
Full Text
View/download PDF

16. The role of soluble tumor necrosis factor receptor types I and II and tumor necrosis factor-(alpha) in malaria during pregnancy

Author

Davison, Billie B., Kaack, M. Bernice, Rogers, Linda B., Rasmussen, Kelsi K., Rasmussen, Terri A., Henson, Elizabeth W., Henson, Michael C., Parekh, Falgunee K., and Krogstad, Donald J.

Subjects
Tumor necrosis factor -- Analysis, Malaria -- Research, Malaria -- Health aspects, Pregnancy -- Research, Pregnancy -- Physiological aspects, Mothers -- Patient outcomes, Mothers -- Causes of, Health
Published
2006

17. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy

Author

Bennett, Jason W., primary, Yadava, Anjali, additional, Tosh, Donna, additional, Sattabongkot, Jetsumon, additional, Komisar, Jack, additional, Ware, Lisa A., additional, McCarthy, William F., additional, Cowden, Jessica J., additional, Regules, Jason, additional, Spring, Michele D., additional, Paolino, Kristopher, additional, Hartzell, Joshua D., additional, Cummings, James F., additional, Richie, Thomas L., additional, Lumsden, Joanne, additional, Kamau, Edwin, additional, Murphy, Jittawadee, additional, Lee, Cynthia, additional, Parekh, Falgunee, additional, Birkett, Ashley, additional, Cohen, Joe, additional, Ballou, W. Ripley, additional, Polhemus, Mark E., additional, Vanloubbeeck, Yannick F., additional, Vekemans, Johan, additional, and Ockenhouse, Christian F., additional

Published
2016
Full Text
View/download PDF

18. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.

Author

Bennett, Jason W., Yadava, Anjali, Tosh, Donna, Sattabongkot, Jetsumon, Komisar, Jack, Ware, Lisa A., McCarthy, William F., Cowden, Jessica J., Regules, Jason, Spring, Michele D., Paolino, Kristopher, Hartzell, Joshua D., Cummings, James F., Richie, Thomas L., Lumsden, Joanne, Kamau, Edwin, Murphy, Jittawadee, Lee, Cynthia, Parekh, Falgunee, and Birkett, Ashley

Subjects
MALARIA vaccines, PLASMODIUM vivax, MALARIA treatment, CIRCUMSPOROZOITE protein, IMMUNE response, PARASITEMIA
Abstract

Background: A vaccine to prevent infection and disease caused by Plasmodium vivax is needed both to reduce the morbidity caused by this parasite and as a key component in efforts to eradicate malaria worldwide. Vivax malaria protein 1 (VMP001), a novel chimeric protein that incorporates the amino- and carboxy- terminal regions of the circumsporozoite protein (CSP) and a truncated repeat region that contains repeat sequences from both the VK210 (type 1) and the VK247 (type 2) parasites, was developed as a vaccine candidate for global use. Methods: We conducted a first-in-human Phase 1 dose escalation vaccine study with controlled human malaria infection (CHMI) of VMP001 formulated in the GSK Adjuvant System AS01B. A total of 30 volunteers divided into 3 groups (10 per group) were given 3 intramuscular injections of 15μg, 30μg, or 60μg respectively of VMP001, all formulated in 500μL of AS01B at each immunization. All vaccinated volunteers participated in a P. vivax CHMI 14 days following the third immunization. Six non-vaccinated subjects served as infectivity controls. Results: The vaccine was shown to be well tolerated and immunogenic. All volunteers generated robust humoral and cellular immune responses to the vaccine antigen. Vaccination did not induce sterile protection; however, a small but significant delay in time to parasitemia was seen in 59% of vaccinated subjects compared to the control group. An association was identified between levels of anti-type 1 repeat antibodies and prepatent period. Significance: This trial was the first to assess the efficacy of a P. vivax CSP vaccine candidate by CHMI. The association of type 1 repeat-specific antibody responses with delay in the prepatency period suggests that augmenting the immune responses to this domain may improve strain-specific vaccine efficacy. The availability of a P. vivax CHMI model will accelerate the process of P. vivax vaccine development, allowing better selection of candidate vaccines for advancement to field trials. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

24. Infectious Disease Risks and Vulnerabilities in the Aftermath of an Environmental Disaster in Minas Gerais, Brazil.

Author

Parekh FK, Yeh KB, Olinger G, and Ribeiro FA

Subjects
Brazil, Cities, Communicable Disease Control, Ecosystem, Environmental Monitoring, Humans, Water Pollutants, Chemical, Communicable Diseases epidemiology, Disasters, Mining, Rivers
Abstract

In January 2019, the state of Minas Gerais experienced another environmental disaster with the collapse of a mining dam near the city of Brumadinho. This disaster has resulted in 256 deaths and 14 people still missing. Toxic mud has contaminated the Paraopeba River resulting in significant fish and wildlife deaths in the river and surrounding areas. The effect of environmental disasters such as this is felt across multiple sectors damaging ecosystems in agriculture, wildlife and human communities. Environmental disasters cause significant disruption of ecosystems, flooding, contamination of water supplies, and displacement of human populations, which can result in increases in transmission and outbreaks of mosquito-borne and zoonotic diseases that can become a serious and long-term public health problem for the region.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results